Send to

Choose Destination
See comment in PubMed Commons below
Ann Surg Oncol. 2002 Aug;9(7):668-74.

Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

Author information

Department of Surgery, University of South Florida, Tampa, FL 33601, USA.


Matrix metalloproteinases (MMPs) have received much attention in recent years for their role in a variety of malignancies. Pancreatic cancer is no exception; MMP-2 and MMP-9 show high levels of expression in clinical and experimental models. Inhibition of MMPs has shown great promise with synthetic inhibitors, such as BB-94, as tumorostatic agents in preclinical models, particularly when these are combined with gemcitabine. These findings have led to several clinical trials using the MMP inhibitors Marimastat and BAY12-9566. Herein, we discuss the roles of MMPs and their inhibition in pancreatic cancer.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center